Guizhou Bailing Group Pharmaceutical Co., Ltd. (SHE:002424)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Intersegment Elimination	-658.25M	-	-	-	-
Industrial	2.49B	2.27B	2.46B	2.29B	2.86B
Industrial Growth	9.35%	-7.72%	7.57%	-19.97%	12.14%
Others	22.80M	36.31M	45.43M	32.37M	28.40M
Others Growth	-37.19%	-20.07%	40.36%	13.97%	14.83%
Medical Institutions	67.86M	64.22M	60.08M	51.78M	57.39M
Medical Institutions Growth	5.66%	6.90%	16.01%	-9.77%	50.66%
Commercial Business	1.13B	1.45B	1.69B	1.16B	162.38M
Commercial Business Growth	-22.15%	-14.31%	45.33%	617.36%	-65.61%
Total	3.05B	3.83B	4.26B	3.54B	3.11B
Total Growth	-20.31%	-10.26%	20.42%	13.79%	0.75%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
China	3.05B	3.83B	4.26B	3.54B	3.11B
China Growth	-20.31%	-10.26%	20.42%	13.79%	0.75%
Total	3.05B	3.83B	4.26B	3.54B	3.11B
Total Growth	-20.31%	-10.26%	20.42%	13.79%	0.75%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 9, 2026

Data Sources Report a data error